Department of Biomedical Laboratory Science, College of Biomedical Science and Engineering and Regional Research Center, Inje University, Gimhae 621-749, Korea.
J Ginseng Res. 2012 Jan;36(1):40-6. doi: 10.5142/jgr.2012.36.1.40.
Ginseng, the root of Panax ginseng Meyer, has been used frequently in traditional oriental medicine and is popular globally. Ginsenosides, which are the saponins in ginseng, are the major components having pharmacological and biological activities, including anti-diabetic and anti-tumor activities. In this study, we investigated the effects of total saponin from Korean red ginseng (TSKRG) on thrombin-produced thromboxane A2 (TXA2), an aggregating thrombogenic molecule, and its associated microsomal enzymes cyclooxygenase (COX)-1 and TXA2 synthase (TXAS). Thrombin (0.5 U/mL) increased TXA2 production up to 169 ng/10(8) platelets as compared with control (0.2 ng/10(8) platelets). However, TSKRG inhibited potently TXA2 production to the control level in a dose-dependent manner, which was associated with the strong inhibition of COX-1 and TXAS activities in platelet microsomes having cytochrome c reductase activity. The results demonstrate TSKRG is a beneficial traditional oriental medicine in platelet-mediated thrombotic diseases via suppression of COX-1 and TXAS to inhibit production of TXA2.
人参是五加科人参属植物人参的根,在传统东方医学中被广泛应用,在全球范围内也广受欢迎。人参皂苷是人参中的主要成分,具有多种药理和生物活性,包括抗糖尿病和抗肿瘤活性。在这项研究中,我们研究了红参总皂苷(TSKRG)对凝血酶产生的血栓素 A2(TXA2)的影响,TXA2 是一种聚集性促血栓形成分子及其相关的微粒体酶环加氧酶(COX)-1 和血栓素 A2 合酶(TXAS)。与对照组(0.2 ng/10(8)血小板)相比,凝血酶(0.5 U/mL)可使 TXA2 的产生增加至 169 ng/10(8)血小板。然而,TSKRG 呈剂量依赖性地强烈抑制 TXA2 的产生,使其恢复至对照水平,同时对具有细胞色素 c 还原酶活性的血小板微粒体中的 COX-1 和 TXAS 活性也具有强烈的抑制作用。研究结果表明,TSKRG 通过抑制 COX-1 和 TXAS 抑制 TXA2 的产生,是一种有益于血小板介导的血栓性疾病的传统东方药物。